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Abstract
Background: Many aspects of clinical management of Lyme neuroborreliosis are subject to intense debates.
Guidelines show considerable variability in their recommendations, leading to divergent treatment regimes.
The most pronounced differences in recommendations exist between guidelines from scientific societies and
from patient advocacy groups. Assessment of the methodological quality of these contradictory guideline
recommendations can be helpful for healthcare professionals.
Methods: Systematic searches were conducted in MEDLINE and databases of four international and national
guideline organizations for guidelines on Lyme neuroborreliosis published from 1999–2014. Characteristics (e.g., year of
publication, sponsoring organization) and key recommendations were extracted from each guideline. Two independent
reviewers assessed the methodological quality of each guideline according to the Appraisal of Guidelines for Research
and Evaluation II (AGREE II) tool. AGREE II scores from guidelines developed by scientific societies and from
patient advocacy groups were compared across domains.
Results: We identified eight eligible guidelines of which n = 6 were developed by scientific societies and n = 2 by
patient advocacy groups. Agreement on AGREE II scores was good (Cohen’s weighted kappa = 0.87, 95 % CI
0.83–0.92). Three guidelines, all from scientific societies, had an overall quality score of ≥ 50 %. Two of them
were recommended for use according to the AGREE II criteria. Across all guidelines, the AGREE II domain with
the highest scores was “Clarity of Presentation” (65, SD 19 %); all other domains had scores < 50 % with the
domain “Applicability” having the lowest scores (4, SD 4 %). Guidelines developed by scientific societies had
statistically significantly higher scores regarding clarity of presentation than guidelines from patient advocacy
groups (p = 0.0151). No statistically significant differences were found in other domains.
Conclusions: Current guidelines on Lyme neuroborreliosis vary in methodological quality and content. Health
care providers and patients need to be aware of this variability in quality when choosing recommendations
for their treatment decisions regarding Lyme neuroborreliosis. No statement can be given on quality of content
and validity of recommendations, as these issues are not subject to assessment with the AGREE II tool and are
prone to individual interpretation of the available evidence by the corresponding guideline panels. To enhance
guideline quality, guideline panels should put more emphasis on linking recommendations to the available evidence,
transparency in reporting how evidence was searched for and evaluated, and the implementation of recommendations
into clinical practice.
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Background
Lyme disease is a tick-borne infectious disease caused by
the spirochete bacterium Borrelia burgdorferi sensu lato.
Lyme disease can affect multiple organ systems, com-
mon manifestations are dermatologic manifestations
(e.g. erythema migrans), Lyme arthritis or Lyme neuro-
borreliosis [1].
Diagnosis of Lyme disease and Lyme neuroborreliosis
is usually based on consensus-derived case definitions
[2]. Tiered case definitions exist regarding likelihood of
diagnosis depending on diagnostic results [3].
Many aspects of disease management are subject to
controversy, sometimes referred to as the ‘Lyme wars’
[4]. Despite the consensus-derived case definitions, con-
troversy further exists on how Lyme disease should be
diagnosed and how it should be treated. Some diagnostic
tests, like the lymphocyte-transformation test, are dis-
couraged by some guidelines [3, 5, 6], whereas other
guidelines recommend the use of this test [7]. What
signs and symptoms are suspicious or typical of Lyme
disease and which symptoms are rather unspecific is
controversial among authors [8, 9]. Therapy of Lyme
disease is another subject of disagreements and intense
debate, including different opinions regarding choice
and dosage of drugs, route of administration and dur-
ation of treatment.
These different opinions resulted in different, partially
contradicting guideline recommendations for Lyme neu-
roborreliosis. One example is duration of treatment, for
which three guidelines (Infectious Diseases Society of
America [IDSA], European Federation of Neurological
Societies [EFNS] and the evidence-based practice param-
eters of the American Academy of Neurology [AAN] [3,
10, 11]) recommend antibiotic treatment with a duration
of up to 14–28 days, whereas the guideline of the Inter-
national Lyme and Associated Diseases Society (ILADS)
states that several months of antibiotic therapy are often
required [8]. These contradicting recommendations have
considerable impact on patient care, as extended anti-
biotic courses put a high burden on patient adherence,
are more expensive, and can even have lethal conse-
quences [12, 13]. The controversy continues with rec-
ommendations for antibiotic treatment of residual
symptoms after treatment [8], whereas other guidelines
discourage repeated antibiotic courses in the absence of
ongoing infection, rather recommending symptomatic
treatment [3].
Furthermore, guidelines from patient advocacy groups
recommend treatment with multiple antibiotic agents
and additional adjuvant agents (e.g. hydroxychloroquine)
simultaneously [7, 8], whereas other guidelines recom-
mend use of single antibiotic agents [3, 5, 10, 11]. The
greatest divergence regarding these contradicting recom-
mendations in different guidelines seems to exist
between guidelines developed by scientific societies and
guidelines from patient advocacy groups.
These divergent, partly contradicting recommendations
lead to uncertainty and doubt in patients and healthcare
providers. Evidence from high-quality studies is scarce for
treatment of Lyme neuroborreliosis and of limited meth-
odological quality. Hence, contradicting guideline recom-
mendations may exist for conditions with limited
evidence, and individual opinions and experiences that are
not evidence-based gain increasing influence on guideline
recommendations. This, in turn, emphasizes the need for
transparent and comprehensible methods for developing
guidelines as a sound basis for clinical decisions. To inves-
tigate methodological rigour of development of these
guidelines with contradicting recommendations, we per-
formed a systematic review focusing on the quality of
guidelines for Lyme neuroborreliosis.
Methods
Data sources and search strategy
We performed a systematic literature search for guide-
lines regarding Lyme neuroborreliosis in MEDLINE (via
Ovid) and the databases of the National Guideline Clear-
inghouse (http://www.guideline.gov/), the International
Guideline Library of the Guidelines International
Network (http://www.g-i-n.net/library/international-
guidelines-library), The National Institute for Health and
Care Excellence (NICE, http://www.nice.org.uk/guid-
ance/published?type=guidelines) and the Arbeitsge-
meinschaft der Wissenschaftlichen Medizinischen
Fachgesellschaften (AWMF, http://www.awmf.org/leitli-
nien/leitlinien-suche.html) from 1999–2014 (Additional
file 1). This search was supplemented by records from
clinical experts. Language was restricted to English and
German due to limited resources.
Data extraction of guideline characteristics
Two reviewers sequentially extracted relevant informa-
tion from each eligible guideline: a first reviewer (RD)
extracted the data, whereas a second reviewer (IT)
checked the first reviewer’s data for completeness and
accuracy. Differences in opinion were resolved through
discussion. Data was collected on year of publication,
country, type of producing organization (scientific soci-
ety or patient advocacy group), as well as key recom-
mendations for diagnosis and treatment of Lyme
neuroborreliosis.
Assessment of methodological quality of guidelines
Methodological quality was assessed using the Appraisal of
Guidelines Research and Evaluation II (AGREE II) instru-
ment [14], which contains 23 items grouped in six domains:
1) scope and purpose; 2) stakeholder involvement; 3) rigour
of development; 4) clarity and presentation; 5) applicability
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and 6) editorial independence. Each domain holds between
2 and 4 items. Two reviewers (RD and IT) independently
rated each item on a 7-point scale, with 1 being the lowest
and 7 the highest rating. In a consensus meeting among the
reviewers, we discussed every item for which the rating dif-
fered by more than 1 point (e.g., 1 versus 3) on the original
7-point scale. Reviewers in turn explained the rationale for
their rating and had the opportunity to revise it where ap-
propriate. After the consensus meeting, agreement between
raters was investigated using Cohen’s weighted kappa and
Lin’s concordance correlation coefficient [15].
From the rating, domain scores were calculated as de-
scribed by AGREE II by the following formula: (obtained
score - minimum possible score) / (maximum possible
score - minimum possible score) The maximum possible
score was: maximum possible score x number of items
in domain x number of appraisers. The minimum pos-
sible score was: minimum possible score x number of
items in domain x number of appraisers. There is no de-
fined threshold for the domain scores of the AGREE II
tool to make a distinction between high quality and low
quality guidelines, albeit some authors consider domain
scores <50 % pragmatically as low quality [16, 17].
According to the AGREE II method, each guideline is
rated as either ‘recommended’, ‘recommended with mod-
ifications’ or ‘not recommended’ taking into account the
appraisal items considered in the assessment process.
If manuals of methodology were accessible for the de-
velopment process of single guidelines, their content was
considered when performing the AGREE II assessment.
As differences in recommendations regarding Lyme
neuroborreliosis from different panels were of interest,
we compared domain scores between them to investi-
gate whether differences may be paralleled by differences
in quality. Additionally, we investigated whether guide-
line quality was associated with year of publication as an
explorative analysis, as guideline quality might increase
over time and availability of rating instruments e.g.
AGREE II. Statistical comparisons between scores were
performed with two-sided t-test. Correlation calculations
were performed with Spearman’s rank correlation coeffi-
cient. Statistical analyses were conducted with R and
Prism 4.0b for Macintosh [18, 19].
As this study does not include any patient data, no
ethical approval or consent was needed.
Results
Guidelines included
We identified 177 records; of which 168 were ex-
cluded (reasons are listed in Fig. 1). After exclusion
of 1 record after full text review, eight eligible guide-
lines could be included for data extraction and quality
assessment. The record excluded in the full text re-
view was an update of another included guideline. As
the scope of the updated guideline was diverted from
therapy of Lyme neuroborreliosis, the updated guide-
line no longer fitted our inclusion criteria and was
excluded. The original version of the guideline was
used for assessment.
Six guidelines were national guidelines. Two guidelines
were developed by international organizations [3, 8] (see
Table 1).
Six of eight included guidelines were developed by
scientific societies [3, 5, 6, 10, 11, 20] and two were
developed by patient advocacy groups [7, 8]. Constitu-
tion of these guideline panels was mostly dominated
by neurologists, illustrating the specificity of the
underlying topic. No guidelines from other organiza-
tions, e.g. public health agencies, were identified. One
guideline had a specific focus on recommendations
for children with Lyme disease and Lyme neuroborre-
liosis [20]. Guidelines from patient advocacy groups
endorsed extended antibiotic treatments longer than
28 days, whereas guidelines from scientific societies
recommended antibiotic treatments for 14–28 days
(Table 1).
Fig. 1 Guideline flow diagram
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Full guideline name (name of responsible body, if not in
title)
Year Country Type of
organization
Key recommendations for diagnosis Key recommendations for therapy
AAN Practice Parameter: Treatment of nervous
system Lyme disease (an evidence-based
review) (American Academy of Neurology)
2007 USA Scientific
society
None, focus on treatment Antibiotic regimens for 14 days, either
oral or parenteral, doxycycline is the
preferred drug for peripheral affections,
for more severe manifestations (meningitis,
encephalomyelitis) parenteral treatments
(ceftriaxone, cefotaxime or penicillin G)
are recommended (alternative
antibiotics specified)
IDSA The Clinical Assessment, Treatment, and
Prevention of Lyme Disease, Human
Granulocytic Anaplasmosis, and Babesiosis:
Clinical Practice Guidelines by the Infectious
Diseases Society of America
2006 USA Scientific
society
No specific recommendations, focus
on treatment
For cranial nerve palsy oral regimen,
other neurologic manifestations
parenteral regimen for 14-28 days,
preferred oral drugs are amoxicillin,
doxycycline and cefuroxime,
preferred parenteral drug is ceftriaxone
(alternative antibiotics specified)
EFNS EFNS guidelines on the diagnosis and





Investigation of CSF/serum pair for
Bb-specific antibodies, intrathecal antibody
production and signs of CSF inflammation.
Diagnosis according to case definitions
(definite/possible).
Early LNB: ceftriaxone IV for 14 days
Late LNB: ceftriaxone IV for 21 days
Peripheral neuropathy + acrodermatitis
chronica atrophicans: doxycycline oral
or ceftriaxone IV for 21 days (alternative
antibiotics specified)
DGN S1-Leitlinie Neuroborreliose
(German Academy of Neurology)
2012 Germany Scientific
society
Investigation of CSF/serum pair for
Bb-specific antibodies, intrathecal antibody
production, specific CSF/serum antibody
index and signs of CSF inflammation (e.g.
pleocytosis). Diagnosis according to case
definitions. (definite/probable/possible)
Early LNB: doxycycline oral for 14 days
(preferred) Late LNB: ceftriaxone IV for
14-21 days (alternative antibiotics specified)
ILADS Evidence assessments and guideline
recommendations in Lyme disease:
the clinical management of known
tick bites, erythema migrans rashes
and persistent disease (The International




No clear recommendations, emphasis
on clinical judgment for diagnosing
Lyme disease
No specific recommendations, discussion
of a wide range of options, including
carbapenems, macrolides, combination
of antibiotics and adjuvant treatments
(hydroxychloroquine), no clear
recommendation for length
of treatment but endorsement of
longer (>30 days) antibiotic courses
DBG Diagnostik und Therapie der




No clear recommendations, discussion
of several diagnostic options
No specific recommendations, discussion
of a range of options, including carbapenems,
macrolides, metronidazole, combination of
antibiotics and adjuvant treatments
(hydroxychloroquine). Length of treatment














Table 1 Characteristics of included guidelines (Continued)
BIA The epidemiology, prevention, investigation and
treatment of Lyme borreliosis in United Kingdom




Single or paired serum tests for Bb antibodies,
intrathecal specific antibody production,
specific CSF/serum antibody index, signs
of CSF inflammation (e.g. pleocytosis)
Isolated facial nerve palsy or uncomplicated
meningitis: doxycycline oral for at least 14 days
Complicated meningitis or late LNB:
ceftriaxone for 14-28 days (alternative
antibiotics specified)
DGPI Diagnostik und Therapie der Lyme-Borreliose im
Kindesalter. Empfehlungen der Deutschen
Gesellschaft für Pädiatrische Infektiologie.
(Diagnosis and therapy of Lyme borreliosis in




No clear recommendations, discussion of
obligate findings like investigation of
CSF/serum pair for Bb-specific antibodies,
intrathecal specific antibody production,
signs of CSF inflammation (e.g. pleocytosis)














Assessment of methodological quality
Discussion on items that were rated >1 point apart by
the two raters had to be performed in all domains. Items
most often discussed were in domain 1 (‘The overall ob-
jective of the guideline is specifically described’, ‘the
guideline development group includes individuals from
all relevant professional groups’) and in domain 3 (‘the
health benefits, side effects, and risks have been consid-
ered in formulating the recommendations’).
Inter-rater agreement was high according to Cohen’s
weighted kappa (κ = 0.87, 95 % CI 0.83–0.92) and Lin’s
concordance correlation coefficient (rho = 0.87, 95 % CI
0.84–0.90). Quality of included guidelines was <50 % in
most AGREE II domains; the only domain with a score
>50 % was clarity of presentation (mean 65 % of the
maximum possible score, SD 19.2 %, Table 2), followed
by the domain scope and purpose (mean 45.1 % of the
maximum possible score, SD 11.4 %). The domain ap-
plicability received the lowest scores across all guidelines
(mean 4.6 % of the maximum possible score, SD 4.1 %),
followed by editorial independence (mean 15.8 % of the
maximum possible score, SD 15.9 %) and rigour of de-
velopment (mean 18.3 % of the maximum possible score,
SD 8.7 %). Three guidelines had a score of ≥50 % in the
item overall guideline quality [3, 11].
Overall two guidelines were rated according to AGREE
II rating as ‘recommended by reviewers’, three as ‘recom-
mended with modifications’, and three were ‘not recom-
mended’ (Table 2).
Scores for domain 3 (‘Rigour of development’) correlate
with ‚Overall guideline assessment’ (Spearman’s r = 0.8537,
p = 0.0107). Other domain scores did not correlate with
‚Overall guideline assessment’ (not shown). Year of guide-
line publication did not correlate with any domain score
(Table 3).
Scope and purpose were often insufficiently described
and had to be derived from the title of the guideline in
most cases. Specific health questions were described in
only one guideline [10], other guidelines addressed gen-
erally broad and unspecific health issues.
The domain stakeholder involvement suffered from
lack of consideration of views and preferences of the tar-
get population.
Systematic methods to search for evidence were only
reported in three guidelines [3, 8, 11]. Only one guide-
line described the applied search strategy in a reprodu-
cible way [11]. Criteria for selecting the evidence and the
methods of formulating recommendations were de-
scribed in two guidelines [3, 11], whereas this process
remained elusive in the other guidelines.
The link between recommendations and supporting
evidence was expressed in most guidelines as a reference
to or a narrative review of the respective evidence. A
systematic assessment of risk of bias of included studies
or a summary of findings table was not presented in any
guideline. Only three guidelines rated the risk of bias for
the available evidence [3, 10, 11], applying levels of evi-
dence ratings in analogy to the Oxford Centre of
Evidence-based Medicine Levels of Evidence [21].
External review was mentioned only in two guidelines
[7, 11]. However, it remained unclear who performed
the review and how it was performed.
Clarity of presentation was acceptable in most guide-
lines, although some guidelines presented only vague




















BIA 2010 0.53 0.11 0.09 0.81 0.08 0 0.33 YM
DBG 2010 0.33 0.28 0.10 0.53 0 0.17 0.25 N
DGN
2012
0.28 0.11 0.17 0.64 0.13 0.17 0.33 N
EFNS
2010
0.47 0.17 0.23 0.81 0.04 0.08 0.58 Y
DGPI
1999
0.33 0.14 0.10 0.69 0.06 0 0.25 N
IDSA
2006
0.61 0.5 0.22 0.86 0.02 0.17 0.5 YM
ILADS
2004
0.56 0.36 0.18 0.22 0.04 0.13 0.42 YM
AAN 2007 0.5 0.31 0.37 0.64 0 0.54 0.5 Y
Mean
(SD)
0.45 (0.11) 0.25 (0.13) 0.18 (0.08) 0.65 (0.19) 0.05 (0.04) 0.16 (0.16) n.a.
aY yes, YM yes with modifications, N = no
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recommendations with considerable ambiguity in dos-
ages, choice of drugs and on actual length of treatment
[7, 8]. Key recommendations were easily identifiable in
most guidelines [6, 7, 10, 11, 20], which provided recom-
mendations in a special box or in a separately provided
clinical pathway [5]. Other guidelines presented recom-
mendations embedded in the continuous text, which
were more difficult to identify [8].
Applicability was insufficiently addressed in almost
every guideline. Potential barriers or resource implica-
tions, like availability of specialized laboratories for
valid serologic testing, were addressed in only three
guidelines [3, 5, 6]. Monitoring and auditing criteria
were not mentioned in any guideline.
Conflicts of interest were not disclosed in three guide-
lines [6, 8, 20]. The other guidelines disclosed conflicts of
interest, but it remained unclear how potential influences
of these conflicts on recommendations were operated.
Guidelines developed by scientific societies scored differ-
ent results than guidelines developed by patient advocacy
groups. Results are shown in Table 4. Guidelines developed
by scientific societies had statistically significantly higher
scores for clarity of presentation (p = 0.0151), differences in
other domains were not statistically significant. Overall
guideline assessment was not significantly different for
guidelines from scientific societies and from patient advo-
cacy groups (p = 0.4534, Table 4).
Discussion
Methodological quality of existing guidelines for treat-
ment of Lyme neuroborreliosis is limited and shows
considerable variability across individual guidelines
identified. Quality assessments of many domains were
unsatisfactory according to the AGREE II tool. Qual-
ity scores partly differed between guidelines developed
by scientific societies and guidelines developed by pa-
tient advocacy groups, with statistically significant dif-
ferences in clarity of presentation. Interestingly
enough, year of publication did not correlate with any
of the quality score, albeit this could be to the low
sample size. Due to language limitations, we may
have missed guidelines which could not be assessed
in this review.
Discussion on items that were rated >1 point apart by
the two raters had to be performed in all domains,
mostly because information on single items was scat-
tered through individual guidelines and was difficult to
gather. Such disagreements could easily be cleared in
the consensus discussion.
Quality assessment of guidelines with the AGREE II
tool covers issues of methodological rigour of guide-
line development, applicability and transparency. No
statement can be given on quality of content and val-
idity of recommendations drawn from the available
body of evidence, as these issues are not subject to
assessment with the AGREE II tool and are prone to
individual interpretation of the available evidence by
the corresponding guideline panels. However, as these
issues cannot be assessed directly, the process of
selecting evidence and linking of recommendations to
supporting evidence in an individual guideline should
be transparent and comprehensible, which was insuffi-
cient in most included guidelines. The importance of
methodological rigour of development for guideline
development is illustrated by our finding that the do-
main score for ‘rigour of development’ correlated sta-
tistically significantly with the overall guideline
assessment.
Whereas clarity of presentation was acceptable in some
guidelines, more emphasis on rigour of development and
especially systematic search methods, criteria for selecting
evidence and linking of recommendations to supporting
evidence as well as addressing applicability issues could lead
to improved quality and better usability of guidelines for
management of Lyme disease. The credibility of a guideline
is diminished when it is not clear whether systematic search
Table 3 Correlation of year of publication and AGREE II domain
scores
Domain Spearman’s r p-value
D1 Scope and purpose −0.4541 0.2675
D2 Stakeholders involvement −0.54 0.171
D3 Rigour of development −0.11 0.793
D4 Clarity of presentation 0.2772 0.5062
D5 Applicability 0.2469 0.5364
D 6 Editorial independence 0.1448 0.7322
Overall quality assessment 0.0248 0.9534
Table 4 Comparison of AGREEII domain scores for guidelines
developed by scientific societies and by patient advocacy groups
Domain Scientific society Advocacy group p- value
Mean SD (range) Mean SD (range)
D1 Scope and purpose 0.478 0.109 0.445 0.115 0.7761
D2 Stakeholders
involvement
0.24 0.0149 0.32 0.04 0.5732
D3 Rigour of
development
0.216 0.092 0.14 0.04 0.2763
D4 Clarity of
presentation
0.752 0.093 0.375 0.155 0.0151*
D5 Applicability 0.054 0.046 0.02 0.02 0.4358
D 6 Editorial
independence
0.192 0.1852 0.15 0.02 0.7976
Overall guideline
assessment
0.42 0.12 0.33 0.83 0.4534
*p < 0.05
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methods were used to gather available evidence or how rec-
ommendations are linked to supporting evidence.
Linkage of recommendations to the available evidence
could be improved by implementing summary of find-
ings tables according to the GRADE approach [22].
Readers could then identify key recommendations more
easily and would be provided with additional informa-
tion on the strengths and weaknesses of the body of
evidence.
Applicability of guidelines could be improved by
providing advice or tools on how the recommenda-
tions can be put into practice, e.g. short versions,
clinical pathways or clear accentuation of key recom-
mendations. Potential resource implications could be
applied, e.g. the need for specialized laboratories on
serologic testing.
Monitoring and auditing criteria were not men-
tioned in any guideline, although it may be difficult
to determine such criteria for treatment of Lyme neu-
roborreliosis. Included guidelines did not intend to
provide monitoring criteria but rather stated that the
intention was to provide support and guidance for cli-
nicians and patients in treatment decision.
In the light of contradicting recommendations in a
field with limited evidence, it seems necessary to pro-
vide guidelines which are transparently developed and
provide evidence based recommendations for clini-
cians. Individual guidelines with highest overall scores
on guideline quality, which were also the two guide-
lines recommended according to AGREE II ratings
were the EFNS and the AAN guidelines.
These two guidelines that were ‘recommended’ accord-
ing to AGREE II had especially high scores in the do-
mains ‘rigour of development’ and ‘clarity of presentation’
compared to the guidelines that were not recommended.
All other guidelines, including the current guideline from
the DGN, were not rated as ‘recommended’.
Both guidelines stem from scientific societies. None
of the guidelines from patient advocacy groups were
rated as ‘recommended’. Guidelines from patient ad-
vocacy groups endorsed extended antibiotic treat-
ments longer than 28 days, whereas guidelines from
scientific societies recommended antibiotic treatments
for 14−28 days. Differences in these recommendations
might partly be explained by differences in methodo-
logical quality of guidelines.
Conclusions
Clinicians and patients faced with treatment decisions
on Lyme neuroborreliosis can use the provided qual-
ity assessment of the available guidelines to choose
individual guidelines showing high methodological
quality according to the AGREE II tool.
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